Form 4: Inozyme Pharma Executive Sanjay Subramanian Reports Stock Purchase

Sanjay Subramanian, SVP, CFO & Head of BD at Inozyme Pharma, reports the purchase of 2,490 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• On March 31, 2025, Sanjay Subramanian, SVP, CFO & Head of BD of Inozyme Pharma, Inc., acquired 2,490 shares of common stock.
• The shares were purchased through the company's 2020 Employee Stock Purchase Plan (ESPP).
• The purchase price was $0.77 per share, calculated as 85% of the closing price of Inozyme Pharma's common stock on March 31, 2025.
• Following the transaction, Subramanian directly owns 32,888 shares of Inozyme Pharma's common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports a routine stock purchase under the ESPP. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• Executive participation in the Employee Stock Purchase Plan can signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, such as officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value.

Stakeholder Impact

• The purchase of shares by a company executive could be viewed positively by shareholders, signaling confidence in the company's future.

Key Dates

Keywords

Inozyme Pharma, Sanjay Subramanian, Form 4, Employee Stock Purchase Plan, INZY, Stock Purchase, Beneficial Ownership